Obermatt
See Similar Stocks →

Fulcrum Therapeutics

NMQ:FULC · US3596161097
PharmaceuticalsSmall

360

24
Medium confidence — indicative
EV / EBIT90
Price / Owner Earnings61
Owner Earnings Yield1
Dividend Yield1
Price/Sales48
Price/Book73
Return on Capital23
Cash Return on Capital29
Return on Equity37
Profit margins4

Cash truth not applicable for financial companies.

Sales growth—
Profit growth39
Reinvestment67
Price momentum4
Debt load73
Refinancing44
Debt Payback1
Liquidity25
Analyst ratings1
Opinion Changes50
Price Target Upside49
Market mood49
Value Creation5/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Fulcrum Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2015
Employees65
Websitefulcrumtx.com
ISINUS3596161097
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
HematologyStem Cell TherapyGenetic DisorderBiotechnologyGeneticsHealth CareTherapeutics

Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The company’s lead product can…

Analysis

Middle-of-the-road

Fulcrum Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is mixed and the balance sheet is stretched. The company scores 5/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
35
2023202420252026

All-time high

72

Mar 2026

All-time low

17

Jan 2024

Average rank

41

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
48
54
3
11
Price/Earnings
64
18
18
18
Price/Book
73
73
62
54
Dividend Yield
1
1
1
1
Value (overall)
76
63
29
39

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Fulcrum Therapeutics with its peers
EyePoint
NMQ:EYPT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ventyx Biosciences
NSQ:VTYX
51
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
CalciMedica
NAQ:CALC
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
LB Pharmaceuticals
NMQ:LBRX
79
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Eledon Pharmaceuticals
NAQ:ELDN
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Terns Pharmaceuticals
NSQ:TERN
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →